Clinical Policy: Mecasermin (Increlex)
Reference Number: ERX.SPA.209
Effective Date: 01.11.17
Last Review Date: 08.21
Line of Business: Commercial, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Mecasermin (Increlex®) is a human insulin-like growth factor-1 (IGF-1).

FDA Approved Indication(s)
Increlex is indicated for the treatment of growth failure (GF) in pediatric patients 2 years of age and older with:
- **Severe primary IGF-1 deficiency (IGFD)**
  
  IGFD is defined by: height standard deviation score ≤ -3.0 and basal IGF-1 standard deviation score ≤ -3.0 and normal or elevated growth hormone (GH).
- **Growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH

Limitation(s) of use:
- Increlex is not a substitute to GH for approved GH indications.
- Increlex is not indicated for use in patients with secondary forms of IGFD, such as GH deficiency, malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory corticosteroids.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

Health plan approved formularies should be reviewed for all coverage determinations. Requirements to use preferred alternative agents apply only when such requirements align with the health plan approved formulary.

It is the policy of health plans affiliated with Envolve Pharmacy Solutions™ that Increlex is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Severe Primary IGF-1 Deficiency (must meet all):
      1. Diagnosis of severe primary IGFD;
      2. Prescribed by or in consultation with a pediatric endocrinologist;
      3. Age ≥ 2 and < 18 years;
      4. If age > 10 years, open epiphysis on x-ray;
      5. IGF-1 serum level is ≥ 3 standard deviations (SD) below the mean;
      6. GH serum level is normal or elevated;
      7. Height is ≥ 3 SD below the mean for age and sex (SD, height, date, and age in months within the last 90 days are required);
      8. Member does not have malignant neoplasia or a history of malignancy;
      9. Somatropin (recombinant human GH) is not prescribed concurrently with Increlex;
      10. Dose does not exceed 0.12 mg/kg twice daily.
   
   Approval duration: 12 months or up to age 18 years, whichever is shorter

   B. Acquired Growth Hormone Insensitivity (must meet all):
      1. Diagnosis of acquired GH insensitivity;
      2. Prescribed by or in consultation with a pediatric endocrinologist;
      3. Age ≥ 2 and < 18 years;
4. If age > 10 years, open epiphysis on x-ray;
5. Documentation of genetic GH deficiency due to a GH gene deletion;
6. Documentation of neutralizing GH antibodies;
7. Member meets (a or b):
   a. Short stature (SS): height is > 2 SD below the mean for age and sex (SD, height, date, and age in months within the last 90 days are required);
   b. GF: one of the following (i, ii, or iii):
      i. Height deceleration across two growth chart percentiles representing > 1 SD below the mean for age and sex (SD and 2 heights, dates, and ages in months at least 6 months apart within the last year are required);
      ii. Growth velocity > 2 SD below the mean for age and sex over 1 year (SD and 2 heights, dates, and ages in months at least 1 year apart within the last year are required);
      iii. Growth velocity > 1.5 SD below the mean for age and sex sustained over 2 years (SD and 2 heights, dates, and ages in months at least 2 years apart within the last two years are required);
8. Member does not have malignant neoplasia or a history of malignancy;
9. Somatropin (recombinant human GH) is not prescribed concurrently withIncrelex;
10. Dose does not exceed 0.12 mg/kg twice daily.

Approval duration: 6 months or up to age 18 years, whichever is shorter

C. Other diagnoses/indications
1. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

II. Continued Therapy
A. All Indications in Section I (must meet all):
1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions or member has previously met initial approval criteria;
2. If member has received treatment for ≥ 1 year, height has increased ≥ 2 cm in the last year as documented by 2 height measurements taken no more than 1 year apart (dates and height measurements are required);
3. Member does not have malignant neoplasia or a history of malignancy;
4. Somatropin (recombinant human GH) is not prescribed concurrently withIncrelex;
5. If request is for a dose increase, new dose does not exceed 0.12 mg/kg twice daily.

Approval duration: 12 months or up to age 18 years, whichever is shorter

B. Other diagnoses/indications (must meet 1 or 2):
1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions and documentation supports positive response to therapy.
   Approval duration: Duration of request or 6 months (whichever is less); or
2. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

III. Diagnoses/Indications for which coverage is NOT authorized:
A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – ERX.PA.01 or evidence of coverage documents;
B. Secondary forms of IGF-1 deficiency, such as:
   1. GH deficiency;
   2. Malnutrition;
   3. Hypothyroidism;
IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key
- FDA: Food and Drug Administration
- GH: growth hormone
- IGF-1: insulin-like growth factor -1
- IGFD: insulin-like growth factor deficiency
- SD: standard deviation

Appendix B: Therapeutic Alternatives
- Not applicable

Appendix C: Contraindications/Boxed Warnings
- Contraindication(s):
  - In pediatric patients with malignant neoplasia or a history of malignancy
  - Known hypersensitivity to mecasermin
  - Intravenous administration
  - In patients with closed epiphyses for growth promotion
- Boxed warning(s): none reported

Appendix D: Primary IGF-1 Deficiency*
- Causes:
  - GH receptor mutations (known as Laron syndrome or the classical model of GH insufficiency)
  - Post-GH receptor mechanisms
    - GH receptor signal transduction
    - IGF-I gene mutations
    - Impaired IGF-1 promoter function
    - Defective stabilization of circulating IGF-I
  - IGF-1 receptor mutations
    Unlike the causes above, IGF-1 levels are normal or elevated in the case of IGF-1 receptor mutations which would render mecasermin therapy ineffective.

*GH production and secretion is normal or above normal; therefore, exogenous GH treatment would be ineffective.

Appendix E: General Information
- Severe primary IGFD includes patients with mutations in the growth hormone receptor (GHR), post-GHR signaling pathway, and IGF-1 gene defects; they are not GH deficient, and therefore, they cannot be expected to respond adequately to exogenous GH treatment.
- Increlex is not intended for use in subjects with secondary forms of IGF-1 deficiency, such as GH deficiency, malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids. Thyroid and nutritional deficiencies should be corrected before initiating treatment.
- Increlex is not a substitute for GH treatment.
- Failure to increase height velocity during the first year of therapy by at least 2 cm/year suggests the need for assessment of compliance and evaluation of other causes of growth failure, such as hypothyroidism, under-nutrition, and advanced bone age.
- CDC recommended growth charts, data tables, and related information that may be helpful in assessing length, height and growth are available at the following link: https://www.cdc.gov/growthcharts/index.htm

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Growth failure in children with severe primary IGFD or with GH gene deletion who have developed neutralizing antibodies to GH</td>
<td>Initial dose: 40 mcg/kg to 80 mcg/kg SC BID. Dose may be increased by 40 mcg/kg per dose up to 120 mcg/kg SC BID</td>
<td>0.12 mg/kg per dose</td>
</tr>
</tbody>
</table>
VI. Product Availability
Multi-dose vial: 40 mg/4 mL

VII. References

Auxology for acquired GH insensitivity

Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Policy created</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>4Q17 Annual Review</td>
<td>12.01.16</td>
<td>01.17</td>
</tr>
<tr>
<td>Converted to new template. Updated approval durations from 3/6 months to 6/12 months. Updated safety information. Added secondary form of IGFD that should be ruled out before use of Inrelex to the Non-FDA approved Indication section.</td>
<td>10.10.17</td>
<td>11.17</td>
</tr>
<tr>
<td>3Q 2018 annual review: divided primary IGFD and GH insensitivity with gene deletion and antibody formation; added documentation of baseline height for evaluation of positive response to treatment at reauthorization; added requirement that somatropin is not used concurrently with Increlex; moved and added all contraindications to section III; references reviewed and updated.</td>
<td>05.15.18</td>
<td>08.18</td>
</tr>
<tr>
<td>3Q 2019 annual review: added “or up to age 18 years, whichever is shorter” to all approval durations; modified initial approval duration for severe primary IGF-1 deficiency from 6 to 12 months; references reviewed and updated.</td>
<td>05.21.19</td>
<td>08.19</td>
</tr>
<tr>
<td>3Q 2020 annual review: open epiphyses added; auxology updated for acquired GH insensitivity to reconcile with somatropin policy; malignancy contraindication added; positive response removed in deference to growth criteria; references reviewed and updated.</td>
<td>06.02.20</td>
<td>08.20</td>
</tr>
</tbody>
</table>
## Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.

This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.

©2017 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein.

### Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>03.23.21</td>
<td>08.21</td>
</tr>
</tbody>
</table>